J Infect Dis. 2022 Feb 15;225(4):603-607.

COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S Fulda[1], Kathleen V Fitch[1], Edgar T Overton[2], Markella V Zanni[1], Judith A Aberg[3], Judith S Currier[4], Michael T Lu[5], Carlos Malvestutto[6], Carl J Fichtenbaum[7], Esteban Martinez[8], Triin Umbleja[9], Pamela S Douglas[10], Heather J Ribaudo[9], Steven K Grinspoon[1]

Abstract

Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.

Keywords: COVID-19; Global Burden of Disease region; human immunodeficiency virus; vaccination.